Cervical Cancer
Conditions
Keywords
CCRT, adjuvant chemotherapy, cisplatin and docetaxel
Brief summary
The standard treatment of local advanced cervical cancer is concurrent chemoradiotherapy. The 3 year disease free survival was about 50-70%. The distant metastasis is the main cause of failure in local advanced cervical cancer treated with 3-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT). The purpose of this study is to investigate the efficacy and tolerance of concurrent and adjuvant chemotherapy with cisplatin and docetaxel for local advanced cervical cancer. It was expected that the 3 year disease free survival would be increased by 10% with this new treatment schedule.
Detailed description
The cervical cancer is the most common malignant gynecological tumor in the developing area. From 1999, the concurrent chemoradiotherapy has been established as the standard treatment for local advanced cervical cancer. The modern radiotherapy techniques, such as 3 dimensional conformal radiotherapy(3D-CRT), intensity modulated radiotherapy(IMRT), image guided 3-dimensional brachytherapy(3D-BT), was widely used for the treatment of cervical cancer. The recently clinical outcome showed that the 3 year local and regional control was more than 90%［1-3］. The distant metastasis has proved to be the main cause of failure and death, especially for the patient with pelvic lymph node metastasis, large volume of tumor and advanced FIGO stage. the data showed that the 3 year distant metastasis free survival and overall survival were 64.7% and 64.6% respectively for the patient with huge pelvic lymph node metastasis and FIGO stage III- IVA. The system treatment pointing at the distant metastasis has become to be the topic of clinical investigation. Dueñas-González A'［4］ study demonstrated that the 3 year progress free survival and distant metastasis free survival has increased by 8.9% and 8.3% by the radial radiotherapy combined with concurrent chemotherapy with weekly gemcitabine and cisplatin and adjuvant chemotherapy with triweekly gemcitabine and cisplatin. Ryu SY［5］ also reported the triweekly concurrent cisplatin with 3 cycles improved survival outcomes compared with weekly concurrent cisplatin. Retrospective studies by Tang and Jelavić-TB［6-7］ suggested that the adjubant chemotherapy after CCRT has better DMFS and OS. The aim of present study is to prospectively investigate the efficacy and safety of concurrent and adjuvant chemotherapy with cisplatin and docetaxel for patients with local advanced cervical cancer, especially for those with FIGO III-IVA with or without pelvic lymph node metastasis and the FIGO IB2-IIB with pelvic lymph node metastasis.
Interventions
in experimental group: cisplatin 60mg/m2, d1,d22;
DRUGconcurrent chemotherapy with docetaxel
in experimental group: docetaxel 60mg/m2, d1,d22;
RADIATIONpelvic radiotherapy
external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
RADIATIONbrachytherapy
CT/MRI guided brachytherapy or x-ray guided brachytherapy
DRUGadjuvant chemotherapy with cisplatin and docetaxel
cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
Sponsors
Air Force Military Medical University, China
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Biopsy-proven, invasive squamous cell carcinoma, adenocarcinoma, or adenosquamouscarcinoma of the cervix 2. FIGO clinical stage IB2-IIB with pelvic lymph node metastasis or FIGO clinical stage III-IVA with or without pelvic lymph node metastasis 3. ECOG performance score 0-1 4. The bone marrow, hepatic and renal function was normal at registration 5. The patients signed informed consent
Exclusion criteria
1. clear cell and small cell neuroendocrine, sarcoma 2. FIGO stage IVB 3. Prior invasive malignancy 4. Prior systemic chemotherapy 5. Prior radiotherapy to the pelvis or abdomen 6. Severe, active co-morbidity 7. Women who are pregnant 8. immunocompromised status
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival | 3 year |
Secondary
| Measure | Time frame |
|---|---|
| overall survival | 3 year |
Countries
China
Contacts
Primary Contactmei shi, professor
Backup Contactying zhang, doctor
Outcome results
None listed